What would be your next line of therapy for a postmenopausal metastatic ER+/Her 2- BC, s/p anastrazole and palbociclib/fulvestrant who has progressive disease and ESR1 mutation on ctDNA?
Answer from: Medical Oncologist at Academic Institution
Patients with metastatic, hormone receptor positive, HER2 negative breast cancer who develop disease progression after aromatase inhibitor followed by fulvestrant and CDK4/6 inhibitor and have tumors with ESR1 mutation represent a therapeutic challenge. In patients whose cancer cells harbor PIK...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
The only other chemotherapy-free alternative I would consider in this scenario would be continuing fulvestrant but adding everolimus. This combination has shown efficacy in patients who progressed on AI by doubling median PFS from 5.1 to 10.3 months based on PrE0102 Phase II study. However, we don't...
Comments
Medical Oncologist at Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Excellent answer. In addition, if the patient has ...
Excellent answer. In addition, if the patient has ...
Medical Oncologist at Florida Cancer Specialists and Research Institute
wow never thought of that, amazing ideas, @Bora Li...
wow never thought of that, amazing ideas, @Bora Li...